CN116829142A - 处理和改善癌症的方法 - Google Patents

处理和改善癌症的方法 Download PDF

Info

Publication number
CN116829142A
CN116829142A CN202280012882.6A CN202280012882A CN116829142A CN 116829142 A CN116829142 A CN 116829142A CN 202280012882 A CN202280012882 A CN 202280012882A CN 116829142 A CN116829142 A CN 116829142A
Authority
CN
China
Prior art keywords
optionally
pharmaceutical
aml
formulation
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280012882.6A
Other languages
English (en)
Chinese (zh)
Inventor
卡特里奥娜·詹姆森
莱斯利·克雷斯·罗伯逊
迈克尔·伯克
拉里萨·巴拉扬
菲比·蒙德拉
凯拉·梅森
雷蒙德·H·迪普
詹姆斯·拉莱尔
托马斯·惠森特
沃伦·C·陈
英格·范德沃夫
佩吉·温特沃斯
马文学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN116829142A publication Critical patent/CN116829142A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280012882.6A 2021-02-01 2022-02-01 处理和改善癌症的方法 Pending CN116829142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144378P 2021-02-01 2021-02-01
US63/144,378 2021-02-01
PCT/US2022/014663 WO2022165398A1 (en) 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer

Publications (1)

Publication Number Publication Date
CN116829142A true CN116829142A (zh) 2023-09-29

Family

ID=82654982

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280012882.6A Pending CN116829142A (zh) 2021-02-01 2022-02-01 处理和改善癌症的方法

Country Status (7)

Country Link
US (1) US20240148688A1 (https=)
EP (1) EP4284519A4 (https=)
JP (2) JP2024506847A (https=)
CN (1) CN116829142A (https=)
AU (1) AU2022214463A1 (https=)
CA (1) CA3206959A1 (https=)
WO (1) WO2022165398A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254465A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
ATE493444T1 (de) 2004-10-18 2011-01-15 Nitto Denko Corp Intrazelluläre peptidabgabe
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
US10675267B2 (en) * 2015-09-23 2020-06-09 The Regents Of The University Of California Methods for detection and eradication of myeloid leukemia stem cells
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法

Also Published As

Publication number Publication date
EP4284519A1 (en) 2023-12-06
EP4284519A4 (en) 2024-12-25
JP2024506847A (ja) 2024-02-15
AU2022214463A1 (en) 2023-09-14
CA3206959A1 (en) 2022-08-04
JP2025065209A (ja) 2025-04-17
US20240148688A1 (en) 2024-05-09
WO2022165398A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
KR102617833B1 (ko) 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
JP5342834B2 (ja) 骨髄線維症処置剤
KR101085203B1 (ko) 의약 전달용 인지질 나노입자
Ling et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
US20210292843A1 (en) Treatment of diseases associated with activated irak
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
CN103501785A (zh) 用于治疗脑肿瘤的csf-1r抑制剂
EP3170503B1 (en) Lipid particles and nucleic acid delivery carrier
US20100203112A1 (en) Composition of cationic phospholipid nanoparticles for effective delivery of nucleic acids
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
WO2015168599A1 (en) Combination therapies targeting mitochondria for cancer therapy
JP2013521314A (ja) 癌の処置のためのチゲサイクリンの使用
JP2025065209A (ja) がんを処置および改善するための方法
US9012422B2 (en) Method of treating acute myelogenous leukemia
US20240108734A1 (en) Methods for treating and ameliorating cancer
WO2019246158A1 (en) Methods of treating cancer with carbenoxolone
US20250339539A1 (en) Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof
US20250243486A1 (en) Compositions and methods for inhibiting stag1 expression and uses thereof
WO2019246163A1 (en) Methods of inducing regulated cell death by administering mlkl modulators
WO2024254465A2 (en) Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration
RU2801665C2 (ru) Фармацевтическая комбинация для лечения рака
US10413564B2 (en) Compositions and methods for combating drug-resistant cancers
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
JP2011105742A (ja) 肺線維症処置剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination